Brief: Impact Biomedical Announces License Agreement With Prophase Labs To Produce And Distribute Viral-Fighting Compound Equivir
28/06/2022 13:25
June 28 (Reuters) - DSS Inc DSS.A :
* IMPACT BIOMEDICAL ANNOUNCES LICENSE AGREEMENT WITH
PROPHASE LABS
TO PRODUCE AND DISTRIBUTE VIRAL-FIGHTING COMPOUND EQUIVIR
Source text for Eikon: ID:nGNX2MW6mY
Further company coverage: DSS.A
Recent news on DSS
See all newsBrief: Dss Withdraws S-1 Registration Statement With SEC
Brief: Dss Reports Going Concern Audit Opinion In 2025 10-K Filing
Brief: Dss Inc Actively Evaluating Acquisition Opportunities Within Folding Carton Space
Brief: Dss, Inc. Announces Pricing Of $1.0 Million Underwritten Public Offering
Brief: DSS’s Subsidiary, Impact Biomedical, Announces Strategic Merger